3-acetylamino-3-methyl-butyric acid | 63879-04-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-acetylamino-3-methyl-butyric acid
• 英文别名: N-acetyl;-β-aminoisobutanoic acid；β-Acetamino-isovaleriansaeure；3-Acetamido-3-methylbuttersaeure；N-Acetyl-β-valin；3-Acetamido-3-methylbutanoic acid
• CAS: 63879-04-9
• 化学式: C₇H₁₃NO₃
• 分子量: 159.185
• InChiKey: WYOMFNVGVILWLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-acetylamino-3-methyl-butyric acid 在 N,N'-二环己基碳二亚胺 作用下， 生成 2,4,4-trimethyl-4,5-dihydro-[1,3]oxazin-6-one
  参考文献：
  名称：

  Black,D.S.C.; Boscacci,A.B., Australian Journal of Chemistry, 1977, vol. 30, p. 1109 - 1116

  摘要：

  DOI：
• 作为产物：
  描述：

  3-甲基-2-丁烯酸乙酯 在 sodium hydroxide 、 硫酸 作用下， 生成 3-acetylamino-3-methyl-butyric acid
  参考文献：
  名称：

  异恶唑烷胺络合物

  摘要：

  Es werden Methoden zur Bestimmung由5-甲基异iso唑3-甲基异ol唑Angegeben。

  DOI：

  10.1002/hlca.19630460215

文献信息

• [EN] CRF RECEPTOR ANTAGONISTS AND METHODS OF USE<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CRF ET MÉTHODES D'UTILISATION
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2021062246A1

  公开（公告）日：2021-04-01

  Compounds are provided herein, as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).

  本文提供了化合物，以及相关的制剂、组合物和治疗方法，用于治疗需要这些治疗的疾病和/或疾病，例如先天性肾上腺皮质增生症（CAH）。
• Organic Compounds
  申请人：Ehrhardt Claus

  公开号：US20080194549A1

  公开（公告）日：2008-08-14

  The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.

  本发明涉及使用(3,4-二-, 3,3,4-三-, 3,4,4-三-或3,3,4,4-四-)取代吡咯烷化合物制备治疗依赖于肾素活性的疾病的药物制剂；使用该类化合物治疗依赖于肾素活性的疾病；该取代吡咯烷化合物亚类的化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病；该取代吡咯烷化合物亚类的新化合物；包括所述取代吡咯烷化合物的药物制剂和/或包括给予所述取代吡咯烷化合物的治疗方法，特别是制备该新取代吡咯烷化合物的方法，以及其合成的新中间体、起始材料和/或部分步骤。
• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Sheppeck James E.

  公开号：US20100075961A1

  公开（公告）日：2010-03-25

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically acceptable salt, or hydrate, thereof, wherein X is (Ia); or X is (Ib); or X is (Ic); (Id) is heterocycle or heteroaryl; E is —N—, —NR 1 —, —O—, —S—, —SO 2 — or —CR 2 —; F is —N—, —NR 1a —, —O—, —S—, —SO 2 — or —CR 2a —; G is N, —NR 1b —, —O—, —S—, —SO 2 — or —CR 2b —, provided that the E-F-G containing heterocyclic ring formed does not contain a S—S or S—O bond, and at least one of E, F and G is a heteroatom; J, J a , M, M a , Q, R x , R y , R 1 , R 1a , R 1b , R 2 , R 2a , R 2b , and R 3 to R 21 , Z, Z a , Z b , and Z c are as defined above.

  提供了一种新型的非类固醇化合物，其结构式（I）及其对映异构体、二对映异构体或其药学上可接受的盐或水合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括炎症和免疫性疾病、肥胖和糖尿病，其中X为（Ia）; 或X为（Ib）; 或X为（Ic）; （Id）为杂环或杂芳基; E为—N—、—NR1—、—O—、—S—、—SO2—或—CR2—; F为—N—、—NR1a—、—O—、—S—、—SO2—或—CR2a—; G为N、—NR1b—、—O—、—S—、—SO2—或—CR2b—，但E、F和G中含有的杂环环不含有S—S或S—O键，且E、F和G中至少有一个是杂原子; J、Ja、M、Ma、Q、Rx、Ry、R1、R1a、R1b、R2、R2a、R2b和R3到R21、Z、Za、Zb和Zc的定义如上所述。
• Organic compounds
  申请人：Novartis AG

  公开号：US07807709B2

  公开（公告）日：2010-10-05

  The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.

  本发明涉及使用（3,4-二-, 3,3,4-三-, 3,4,4-三-或3,3,4,4-四-）取代吡咯烷化合物来制备用于治疗依赖于肾素活性的疾病的药物制剂；该类化合物在治疗依赖于肾素活性的疾病中的使用；属于这些取代吡咯烷化合物亚类的化合物用于诊断和治疗温血动物，特别是用于治疗依赖于肾素活性的疾病（=失调）；属于这些取代吡咯烷化合物亚类的新化合物；包含所述取代吡咯烷化合物的药物制剂，和/或包括给予所述取代吡咯烷化合物的治疗方法，一种用于特别制备这些新的取代吡咯烷化合物的方法，以及其合成的新中间体，起始材料和/或部分步骤。
• Ligand-Enabled γ-C(sp³)–H Hydroxylation of Free Amines with Aqueous Hydrogen Peroxide
  作者：Zhen Li、Jin-Quan Yu

  DOI：10.1021/jacs.3c09340

  日期：2023.12.6

  of primary amines (1°), piperidines, and morpholines (2°) were hydroxylated at the γ-position with excellent monoselectivity. This method provides an avenue for the synthesis of a wide range of amines, including γ-amino alcohols, β-amino acids, and azetidines. The retention of chirality in the reaction allows rapid access to chiral amines starting from the abundant chiral amine pool.

  通过钯催化对丰度胺原料中的 γ-C-H 键进行选择性氧化是合成和药物化学中一项有价值的转变。尽管在过去十年中在这一主题上取得了进展，但仍然存在两个重大限制：脂肪胺的 C-H 活化需要一个外源性定向基团，除了空间受阻的 α-叔胺，并且迄今为止尚未开发出使用绿色氧化剂（如氧或过氧化氢水溶液）进行 C（sp3）-H 羟基化的实用催化系统。在此，我们报道了使用可持续过氧化氢水溶液 （7.5–10%，w/w） 的配体选择性 γ-C（sp3）-H 羟基化。在 CarboxPyridone 配体的支持下，一系列伯胺 （1°）、哌啶和吗啉 （2°） 在 γ 位以优异的单选择性被羟基化。该方法为合成多种胺提供了一种途径，包括 γ-氨基醇、β-氨基酸和氮杂环胺。反应中手性的保留允许从丰富的手性胺池开始快速获得手性胺。